Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence

Heide Jackson, Kara Mandell, Kimberly Johnson, Debanjana Chatterjee, David J. Vanness

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Background: The aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers. Methods: A Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18-65 over a 6-month period from the state health program perspective. Results: XR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment. Conclusions: XR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.

Original languageEnglish (US)
Pages (from-to)226-231
Number of pages6
JournalSubstance Abuse
Volume36
Issue number2
DOIs
StatePublished - Apr 3 2015

Keywords

  • Cost-effectiveness
  • XR-NTX
  • opioid dependence

Fingerprint Dive into the research topics of 'Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence'. Together they form a unique fingerprint.

Cite this